We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been recognized as an IAM Global Leader 2026. To qualify, individuals must first be ranked in the gold tier of the IAM Patent 1000. From that group, IAM chooses select individuals who merit special attention ”for their ability to innovate, inspire and go above and beyond to deliver value for their clients.”

IAM has published a longer Q&A article featuring Jennifer where she answers questions about her unique career path, advice to biopharma start-ups, latest “hot IP topics”, and her approach to patent portfolio strategy. Feel free to check it out!


Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

Our Past Events

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

26 November 2025

Eagle IP is Coming to San Francisco and Washington DC!

15 October 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

12 June 2025

Recommended Insights

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

28 February 2024
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]
Read more >

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

1 April 2025
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
Read more >

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

10 January 2023
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]
Read more >

From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

21 October 2025
As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]
Read more >
Top crossarrow-right